NCT01875926View on ClinicalTrials.gov

ALX-0171 Phase I Pharmacokinetic Study in Healthy Male Volunteers

PHASE1CompletedINTERVENTIONAL
Enrollment

44

Participants

Timeline

Start Date

May 31, 2013

Primary Completion Date

October 31, 2013

Study Completion Date

October 31, 2013

Conditions
HealthyRSV Infection
Interventions
BIOLOGICAL

ALX-0171

single dose of 200 mg ALX-0171 via oral inhalation

BIOLOGICAL

ALX-0171

repeated doses of 200 mg ALX-0171 via oral inhalation once daily for 5 consecutive days

BIOLOGICAL

ALX-0171

Single dose of 0.3 mg/kg body weight ALX-0171 via intravenous administration

Trial Locations (1)

Unknown

Antwerp

All Listed Sponsors
lead

Ablynx, a Sanofi company

INDUSTRY

NCT01875926 - ALX-0171 Phase I Pharmacokinetic Study in Healthy Male Volunteers | Biotech Hunter | Biotech Hunter